The cellular and molecular pathways affected by IL-12p40/IL-23p40 blockade with ustekinumab in the synovium of psoriatic arthritis (PsA) patients.. p40 blockade with ustekinumab in PsA

Psoriatic arthritis (PsA) is a chronic inflammatory joint disease within the spondyloarthritis spectrum. IL-12p40/IL-23p40 blockade reduces PsA disease activity, but its impact on synovial inflammation remains unclear. We investigated the cellular and molecular pathways affected by IL-12p40/IL-23p40 blockade in the synovium of PsA patients by RNA-sequencing of eleven paired synovial tissue samples treated for twelve weeks with ustekinumab.